Collectively, these results position uPA inhibition as a promising strategy to potentiate antitumor immunity and improve immunotherapy outcomes in prostate cancer, with the combination regimen demonstrating significantly enhanced efficacy compared to monotherapies. The gene discussed is PLAU; the disease is prostate carcinoma.